Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4494-4504

  Clark, Steven S ^a,b   Zhong, Li ^a,b   Filiault, Daniele ^a,b   Perman, Sarah ^a,b   Ren, Zhibin ^a,b   Gould, Michael ^a,b   Yang, Xinhai ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BCR ABL PROTEIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PERILLYL ALCOHOL;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE G1 PHASE; CELL KINETICS; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWNSTREAM PROCESSING; DRUG MECHANISM; ENZYME MECHANISM; FARNESYLATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LEUKEMIA; MITOSIS INHIBITION; PRENYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TRANSFORMED; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MONOTERPENES; ONCOGENE PROTEIN P21(RAS); PERILLA; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0141925956     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Lewis, T. S., Shapiro, P. S., and Ahn, N. G. Signal transduction through MAP kinase cascades. Adv. Cancer Res., 74: 49-139, 1998.
2. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
3. Ahuja, H. G., Foti, A., Bar-Eli, M., and Cline, M. J. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75: 1684-1690, 1990.
4. Sawyers, C. L., and Denny, C. T. Chronic myelomonocytic leukemia: Tel-a-kinase what Ets all about. Cell, 77: 171-173, 1994.
5. Radich, J. P., Kopecky, K. J., Willman, C. L., Weick, J., Head, D., Appelbaum, F., and Collins, S. J. N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood, 76: 801-807, 1990.
6. Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R., Silver, R. T., Schiffer, C. A., Mayer, R. J., Ball, E. D., Wurster-Hill, D., and Bloomfield, C. D. Prognostic importance of mutations in the ras protooncogenes in de novo acute myeloid leukemia. Blood, 83: 1603-1611, 1994.
7. Neri, A., Knowles, D. M., Greco, A., McCormick, F., and Dalla-Favera, R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85: 9268-9272, 1988.
8. Cogswell, P. C., Morgan, R., Dunn, M., Neubauer, A., Nelson, P., Poland-Johnston, N. K., Sandberg, A. A., and Liu, E. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood, 74: 2629-2633, 1989.
9. Hirsch-Ginsberg, C., LeMaistre, A. C., Kantarjian, H., Talpaz, M., Cork, A., Freireich, E. J., Trujillo, J. M., Lee, M. S., and Stass, S. A. RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. Blood, 76: 1214-1219, 1990.
10. Byrne, J. L., and Marshall, C. J. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br. J. Haematol., 100: 256-264, 1998.
11. Beaupre, D. M., and Kurzrock, R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol., 17: 1071-1079, 1999.
12. Reuter, C. W., Morgan, M. A., and Bergmann, L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?. Blood, 96: 1655-1669, 2000.
13. DeClue, J. E., Papageorge, A. G., Fletcher, J. A., Diehl, S. R., Ratner, N., Vass, W. C., and Lowy, D. R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell, 69: 265-273, 1992.
14. Basu, T. N., Gutmann, D. H., Fletcher, J. A., Glover, T. W., Collins, F. S., and Downward, J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (Lond.), 356: 713-715, 1992.
15. Mandanas, R. A., Leibowitz, D. S., Gharehbaghi, K., Tauchi, T., Burgess, G. S., Miyazawa, K., Jayaram, H. N., and Boswell, H. S. Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood, 82: 1838-1847, 1993.
16. Skorski, T., Kanakaraj, P., Ku, D. H., Nieborowska-Skorska, M., Canaani, E., Zon, G., Perussia, B., and Calabretta, B. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med., 179: 1855-1865, 1994.
17. Puil, L., Liu, J., Gish, G., Mbamalu, G., Bowtell, D., Pelicci, P. G., Arlinghaus, R., and Pawson, T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J., 13: 764-773, 1994.
18. Pendergast, A. M., Quilliam, L. A., Cripe, L. D., Bassing, C. H., Dai, Z., Li, N., Batzer, A., Rabun, K. M., Der, C. J., and Schlessinger, J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell, 75: 175-185, 1993.
19. Sawyers, C. L., McLaughlin, J., and Witte, O. N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med., 181: 307-313, 1995.
20. Clark, S. S., Crist, W. M., and Witte, O. N. Molecular pathogenesis of Ph-positive leukemias. Ann. Rev. Med., 40: 113-122, 1989.
21. Raitano, A. B., Halpern, J. R., Hambuch, T. M., and Sawyers, C. L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA, 92: 11746-11750, 1995.
22. Kabarowski, J. H., Allen, P. B., and Wiedemann, L. M. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J., 13: 5887-5895, 1994.
23. Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M., and Kantarjian, H. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 101: 1692-1697, 2003.
24. Woessmann, W., and Mivechi, N. F. Role of ERK activation in growth and erythroid differentiation of K562 cells. Exp. Cell Res., 264: 193-200, 2001.
25. Kang, C. D., Yoo, S. D., Hwang, B. W., Kim, K. W., Kim, D. W., Kim, C. M., Kim, S. H., and Chung, B. S. The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells. Leuk. Res., 24: 527-534, 2000.
26. Kano, Y., Akutsu, M., Tsunoda, S., Mano, H., Sato, Y., Honma, Y., and Furukawa, Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 97: 1999-2007, 2001,
27. Fang, G., Kim, C. N., Perkins, C. L., Ramadevi, N., Winton, E., Wittmann, S., and Bhalla, K. N. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 96: 2246-2253, 2000.
28. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
29. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
30. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
31. Druker, B. Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin. Hematol., 38: 9-14, 2001.
32. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science (Wash. DC), 293: 876-880, 2001.
33. Mills, J. J., Chari, R. S., Boyer, I. J., Gould, M. N., and Jirtle, R. L. Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res., 55: 979-983, 1995.
34. Haag, J. D., Lindstrom, M. J., and Gould, M. N. Limonene-induced regression of mammary carcinomas. Cancer Res., 52: 4021-4026, 1992,
35. Stark, M. J., Burke, Y. D., McKinzie, J. H., Ayoubi, A. S., and Crowell, P. L. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett., 96: 15-21, 1995.
36. Reddy, B. S., Wang, C. X., Samaha, H., Lubet, R., Steele, V. E., Kelloff, G. J., and Rao, C. V. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res., 57: 420-425, 1997.
37. Stayrook, K. R., McKinzie, J. H., Burke, Y. D., Burke, Y. A., and Crowell, P. L. Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells. Carcinogenesis (Lond.), 18: 1655-1658, 1997.
38. Barthelman, M., Chen, W., Gensler, H. L., Huang, C., Dong, Z., and Bowden, G. T. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res., 58: 711-716, 1998.
39. Crowell, P. L., Lin, S., Vedejs, E., and Gould, M. N. Identification of metabolites of the antitumor agent d-limonene capable of inhibiting protein isoprenylation and cell growth. Cancer Chemother. Pharmacol., 31: 205-212, 1992.
40. Ren, Z., and Gould, M. N. Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. Cancer Lett., 76: 185-190, 1994.
41. Crowell, P. L., Ren, Z., Lin, S., Vedejs, E., and Gould, M. N. Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem. Pharmacol., 47: 1405-1415, 1994.
42. Gelb, M. H., Tamanoi, F., Yokoyama, K., Ghomashchi, F., Esson, K., and Gould, M. N. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Lett., 91: 169-175, 1995.
43. Crowell, P. L., Chang, R. R., Ren, Z. B., Elson, C. E., and Gould, M. N. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen D-limonene and its metabolites. J. Biol. Chem., 266: 17679-17685, 1991.
44. Schulz, S., Buhling, F., and Ansorge, S. Prenylated proteins and lymphocyte proliferation: inhibition by d-limonene related monoterpenes. Eur. J. Immunol., 24: 301-307, 1994.
45. Stayrook, K. R., McKinzie, J. H., Barbhaiya, L. H., and Crowell, P. L. Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res., 18: 823-828, 1998.
46. Crowell, P. L., Kennan, W. S., Haag, J. D., Ahmad, S., Vedejs, E., and Gould, M. N. Chemoprevention of mammary carcinogenesis by hydroxylated derivatives of D-limonene. Carcinogenesis (Lond.), 13: 1261-1264, 1992.
47. Gould, M. N. Prevention and therapy of mammary cancer by monoterpenes. J. Cell. Biochem., (Suppl. 22): 139-144, 1995.
48. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Wash. DC), 260: 1934-1937, 1993.
49. Sahin, M. B., Perman, S. M., Jenkins, G., and Clark, S. S. Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia (Baltimore), 13: 1581-1591, 1999.
50. Bedi, A., Barber, J. P., Bedi, G. C., el-Deiry, W. S., Sidransky, D., Vala, M. S., Akhtar, A. J., Hilton, J., and Jones, R. J. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86: 1148-1158, 1995.
51. Nishii, K., Kabarowski, J. H., Gibbons, D. L., Griffiths, S. D., Titley, I., Wiedemann, L. M., and Greaves, M. F. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene, 13: 2225-2234, 1996.
52. Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., and Witte, O. N. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (Wash. DC), 235: 85-88, 1987.
53. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem., 273: 18623-18632, 1998.
54. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J., 351: 95-105, 2000.
55. Clark, S. S., Perman, S. M., Sahin, M. B., Jenkins, G., and Elegbede, J. A. Antileukemia activity ofperillyl alcohol (POH): Uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl transformed cells is to induce growth arrest. Leukemia (Baltimore), 16: 213-222, 2002.
56. Ren, Z., Elson, C. E., and Gould, M. N. Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem. Pharmacol., 54: 113-120, 1997.
57. Okabe, M., Uehara, Y., Noshima, T., Itaya, T., Kunieda, Y., and Kurosawa, M. In vivo antitumor activity of herbimycin A. a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk. Res., 18: 867-873, 1994.
58. Ren, Z., and Gould, M. N. Modulation of small G protein isoprenylation by anticancer monoterpenes in in situ mammary gland epithelial cells. Carcinogenesis (Lond.), 19: 827-832, 1998.
59. Ulsh, L. S., and Shih, T. Y. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Mol. Cell. Biol., 4: 1647-1652, 1984.
60. Haag, J. D., and Gould, M. N. Mammary carcinoma regression induced by perillyl alcohol, a hydroxylated analog of limonene. Cancer Chemother. Pharmacol., 34: 477-483, 1994.
61. Ripple, G. H., Gould, M. N., Arzoomanian, R. Z., Alberti, D., Feierabend, C., Simon, K., Binger, K., Tutsch, K. D., Pomplun, M., Wahamaki, A., Marnocha, R., Wilding, G., and Bailey, H. H. Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin. Cancer Res., 6: 390-396, 2000.
62. Hudes, G. R., Szarka, C. E., Adams, A., Ranganathan, S., McCauley, R. A., Weiner, L. M., Langer, C. J., Litwin, S., Yeslow, G., Halberr, T., Qian, M., and Gallo, J. M. Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies. Clin. Cancer Res., 6: 3071-3080, 2000.
63. Cortez, D., Reuther, G., and Pendergast, A. M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene, 15: 2333-2342, 1997.
64. Yu, C., Krystal, G., Varticovksi, L., McKinstry, R., Rahmani, M., Dent, P., and Grant, S. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res., 62: 188-199, 2002.
65. Salomoni, P., Wasik, M. A., Riedel, R. F., Reiss, K., Choi, J. K., Skorski, T., and Calabretta, B. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med., 187: 1995-2007, 1998.
66. Neshat, M. S., Raitano, A. B., Wang, H. G., Reed, J. C., and Sawyers, C. L. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol. Cell. Biol., 20: 1179-1186, 2000.
67. Mansour, S. J., Candia, J. M., Matsuura, J. E., Manning, M. C., and Ahn, N. G. Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. Biochemistry, 35: 15529-15536, 1996.
68. Shapiro, P. S., and Ahn, N. G. Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1). J. Biol. Chem., 273: 1788-1793, 1998.
69. Heriche, J. K., Lebrin, F., Rahilloud, T., Leroy, D., Chambaz, E. M., and Goldberg, Y. Regulation of protein phosphatase 2A by direct interaction with casein kinase 2α. Science (Wash. DC), 276: 952-955, 1997.
70. Frost, J. A., Alberts, A. S., Sontag, E., Guan, K., Mumby, M. C., and Feramisco, J. R. Simian virus 40 small t antigen cooperates with mitogen-activated kinases to stimulate AP-1 activity. Mol. Cell. Biol., 14: 6244-6252, 1994.
71. Sontag, E., Fedorov, S., Kamibayashi, C., Robbins, D., Cobb, M., and Mumby, M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell, 75: 887-897, 1993.
72. Manfroid, I., Martial, J. A., and Muller, M. Inhibition of protein phosphatase PP1 in GH3B6, but not in GH3 cells, activates the MEK/ ERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPB/p300. Mol. Endocrinol., 15: 625-637, 2001.
73. Cohen, P., Holmes, C. F., and Tsukitani, Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem. Sci., 15: 98-102, 1990.
74. Bialojan, C., and Takai, A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem. J., 256: 283-290, 1988.
75. Catling, A. D., Eblen, S. T., Schaeffer, H. J., and Weber, M. J. Scaffold protein regulation of mitogen-activated protein kinase cascade. In: W. Balch, C. J. Der, and A. Hall (eds.), Regulators and Effectors of Small GTPases, Part F: Ras Family I, Vol. 332, pp. 368-387. New York: Academic Press, 2001.
76. Yu, W., Fantl, W. J., Harrowe, G., and Williams, L. T. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. Curr. Biol., 8: 56-64, 1998.
77. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., and Marsters, J. C. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Wash. DC), 260: 1937-1942, 1993.
78. Hoshino, R., Chatani, Y., Yamori, T., Tsuruo, T., Oka, H., Yoshida, O., Shimada, Y., Ari-i, S., Wada, H., Fujimoto, J., and Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 18: 813-822, 1999.
79. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 99: 1478-1483, 1997.
80. Mandell, J. W., Hussaini, I. M., Zecevic, M., Weber, M. J., and VandenBerg, S. R. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am. J. Pathol., 153: 1411-1423, 1998.